<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25412347</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication.</ArticleTitle><Pagination><StartPage>e111331</StartPage><MedlinePgn>e111331</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e111331</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0111331</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV-A71) is a neurotropic virus that can cause severe complications involving the central nervous system. No effective antiviral therapeutics are available for treating EV-A71 infection and drug discovery efforts are rarely focused to target this disease. Thus, the main goal of this study was to discover existing drugs with novel indications that may effectively inhibit EV-A71 replication and the inflammatory cytokines elevation. In this study, we showed that LiCl, a GSK3&#x3b2; inhibitor, effectively suppressed EV-A71 replication, apoptosis and inflammatory cytokines production (Interleukin 6, Interleukin-1&#x3b2;) in infected cells. Furthermore, LiCl and an immunomodular agent were shown to strongly synergize with each other in suppressing EV-A71 replication. The results highlighted potential new treatment regimens in suppressing sequelae caused by EV-A71 replication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Hui-Chen</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Shin-Ru</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Medical Biotechnology &amp; Laboratory Science, Chang Gung University, Tao-Yuan, Taiwan; Clinical Virology Laboratory, Department of Clinical Pathology, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan; Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Teng-Yuan</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Ming-Yu</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>John T-A</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan; Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003437">Crotonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006885">Hydroxybutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014052">Toluidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1C058IKG3B</RegistryNumber><NameOfSubstance UI="C527525">teriflunomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>G4962QA067</RegistryNumber><NameOfSubstance UI="D018021">Lithium Chloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003437" MajorTopicYN="N">Crotonates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006885" MajorTopicYN="N">Hydroxybutyrates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018021" MajorTopicYN="N">Lithium Chloride</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014052" MajorTopicYN="N">Toluidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25412347</ArticleId><ArticleId IdType="pmc">PMC4239034</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0111331</ArticleId><ArticleId IdType="pii">PONE-D-14-28507</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch MA, Roos R (2007) Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Knipe DM, editor. Fields Virology.Philadelphia: Wolters Kluwer Lippincott Williams &amp;Wilkins. pp.839&#x2013;893.</Citation></Reference><Reference><Citation>Knowles NJ, Hovi T, Hyypi&#xe4; T, King AMQ, Lindberg AM, et al... (2012) Picornaviridae. In: Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses. Ed: King, AMQ, Adams, MJ, Carstens, EB and Lefkowitz, EJ San Diego: Elsevier: pp 855&#x2013;880.</Citation></Reference><Reference><Citation>Ho M (2000) Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect 33: 205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11269363</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HI, Weng KF, Shih SR (2012) Viral and host factors that contribute to pathogenicity of enterovirus 71. Future Microbiol 7: 467&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">22439724</ArticleId></ArticleIdList></Reference><Reference><Citation>Gau SS, Chang LY, Huang LM, Fan TY, Wu YY, et al. (2008) Attention-deficit/hyperactivity-related symptoms among children with enterovirus 71 infection of the central nervous system. Pediatrics 122: e452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">18606624</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR (2010) Neural pathogenesis of enterovirus 71 infection. Microbes Infect 12: 505&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Lee YP, Hung YT, Lin CH, Chuang JI, et al. (2011) Exogenous interleukin-6, interleukin-13, and interferon-gamma provoke pulmonary abnormality with mild edema in enterovirus 71-infected mice. Respir Res 12: 147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223501</ArticleId><ArticleId IdType="pubmed">22054060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Su LY, Wu JM, Yu CK, et al. (2007) Cerebrospinal fluid cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. Clin Microbiol Infect 13: 677&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">17441979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY (2003) Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 36: 269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Foo DG, Trasti SL, Tan EL, Alonso S (2011) Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 85: 3067&#x2013;3076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Liu CC (2012) Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin Dev Immunol 2012: 876241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3432373</ArticleId><ArticleId IdType="pubmed">22956971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Stollar V, Lin JY, Chang SC, Chen GW, et al. (2004) Identification of genes involved in the host response to enterovirus 71 infection. J Neurovirol 10: 293&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WR, Chen YY, Yang SM, Chen YL, Horng JT (2005) Phosphorylation of PI3K/Akt and MAPK/ERK in an early entry step of enterovirus 71. Life Sci 78: 82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094582</ArticleId><ArticleId IdType="pubmed">16150462</ArticleId></ArticleIdList></Reference><Reference><Citation>Beurel E, Michalek SM, Jope RS (2010) Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 31: 24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818223</ArticleId><ArticleId IdType="pubmed">19836308</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Lai YK, Yu CK, Juang JL (2007) Enterovirus 71 triggering of neuronal apoptosis through activation of Abl-Cdk5 signalling. Cell Microbiol 9: 2676&#x2013;2688.</Citation><ArticleIdList><ArticleId IdType="pubmed">17581253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, et al. (2002) The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 34 Suppl 2S52&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Chen TC, Fang MY, Yen KJ, Shih SR, et al. (2010) Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob Chemother 65: 676&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110181</ArticleId><ArticleId IdType="pubmed">20089540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">1867954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Tseng CP, Yang JM, Ju YW, Tseng SN, et al. (2009) Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Res 81: 123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114187</ArticleId><ArticleId IdType="pubmed">19014974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji WT, Liu HJ (2008) PI3K-Akt signaling and viral infection. Recent Pat Biotechnol 2: 218&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">19097333</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin CF, Cloutier A, Ear T, Sylvain-Prevost S, Mayer TZ, et al. (2011) A class IA PI3K controls inflammatory cytokine production in human neutrophils. Eur J Immunol 41: 1709&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">21469098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, et al. (2011) Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis 203: 1784&#x2013;1790.</Citation><ArticleIdList><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Shih SR, Chang TY, Tseng HY, Shih YF, et al. (2008) A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal Biochem 375: 115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">18190777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JT, et al. (2008) Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem 16: 7388&#x2013;7398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Brown J, Martin M (2011) Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53: 130&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021641</ArticleId><ArticleId IdType="pubmed">21095632</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger D, Begue-Pastor N, Benavent S, Gruaz L, Kaufmann MT, et al. (2003) The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 42: 89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509619</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn T, Toyka K, Hartung HP, Jung S (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124: 1791&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522581</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">6382953</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne CB, Bozym R, Morosky SA, Hanna SL, Mukherjee A, et al. (2011) Comparative RNAi screening reveals host factors involved in enterovirus infection of polarized endothelial monolayers. Cell Host Microbe 9: 70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048761</ArticleId><ArticleId IdType="pubmed">21238948</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza R, Rajji TK, Mulsant BH, Pollock BG (2011) Use of lithium in the treatment of bipolar disorder in late-life. Curr Psychiatry Rep 13: 488&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">21847537</ArticleId></ArticleIdList></Reference><Reference><Citation>Freland L, Beaulieu JM (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5: 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282483</ArticleId><ArticleId IdType="pubmed">22363263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez F, Lucas JJ, Avila J (2012) GSK3 and Tau: Two Convergence Points in Alzheimer's Disease. J Alzheimers Dis.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Zhang J, Wong BW, Si X, Wong J, et al. (2005) Inhibition of glycogen synthase kinase 3beta suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin. Cell Death Differ 12: 1097&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">15905881</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao WW, Kao PN, Aoki Y, Xu JC, Shorthouse RA, et al. (1996) A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 28: 3079&#x2013;3080.</Citation><ArticleIdList><ArticleId IdType="pubmed">8962191</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35: 1270&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">8573583</ArticleId></ArticleIdList></Reference><Reference><Citation>Si HF, Lv X, Guo A, Jiang H, Li J (2008) Suppressive effect of leflunomide on rat hepatic stellate cell proliferation involves on PDGF-BB-elicited activation of three mitogen-activated protein kinases. Cytokine 42: 24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343153</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna SK, Aggarwal BB (1999) Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162: 2095&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pubmed">9973483</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong AS, Zeng H, Knight DA, Shen J, Meister GT, et al. (2006) Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 6: 69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16433758</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung YH, Moon KC, Ha JW, Kim SJ, Ha IS, et al... (2012) Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant.</Citation><ArticleIdList><ArticleId IdType="pubmed">23210794</ArticleId></ArticleIdList></Reference><Reference><Citation>Henao-Martinez AF, Weinberg A, Waldman WJ, Levi ME (2012) Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man. J Clin Virol 54: 276&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">22465339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chacko B, John GT (2012) Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis 14: 111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">22093814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu WL, Ho LJ, Chen PC, Tsai YT, Hsu ST, et al. (2011) Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells. J Clin Immunol 31: 1065&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">21845515</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn MC, Knight DA, Waldman WJ (2011) Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 16: 309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML (2011) Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 108: 5777&#x2013;5782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078400</ArticleId><ArticleId IdType="pubmed">21436031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, et al. (2002) Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91: 632&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162592</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>